Quality. Proven

Opthalmics

Nasal formulations

Topical formulations

Oral formulations

Wound care

Vaccines

Personal care

Medical devices

Contraception formulations

Veterinary products

Antiseptic agents

Diagnostic testing and other analysis

Personal care

Medical devices

Contraception formulations

Veterinary products

Antiseptic agents

Diagnostic testing and other analysis

Regulations don’t compromise.
Neither can you.

It’s not only the authorities who demand proven quality, purity and traceability every time. You do. That’s why our Quats are manufactured to the strictest cGMP regulations, and not a single ingredient is delivered without meeting your own uncompromising standards. Whether it is Benzalkonium Chloride, CTAB, Cetrimide or Strong Cetrimide Solution for ophthalmic, nasal sprays, topicals, oral products or medical devices, our cGMP Quats can be used as excipients or APIs across a variety of applications. We know that your business depends upon absolute confi dence in your supplier – so we’ve built our business to deliver the reliability you need. Excellence. Multiplied.

Learn more about our full range of pharma grade Quats at novonordiskpharmatech.com

Visit us at

Stand #42D32

(HALL 4.2)

Go to article: Home | Improving safety for multiple drug regimes Go to article: In this issueGo to article: ContentsGo to article: Curtis Health CapsGo to article: Astrix Go to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Owen Mumford Company Insight Go to article: Owen MumfordGo to article: CommentGo to article: Use of AI in the fight against Covid-19 shows mixed results Go to article: What does Ireland’s tax hike mean for pharma?Go to article: Chinese review designations lag behind US and EUGo to article: The business benefits of text mining in life sciencesGo to article: Mettler ToledoGo to article: HOF SonderanlagenbauGo to article: In DepthGo to article: Narrow FDA panel vote on Merck’s molnupiravir bolsters outlook on mAbsGo to article: The challenges of multiple drugs safety reportingGo to article: 3D printing in drug manufacturing: unlocking future possibilitiesGo to article: Can drug repurposing uncover better treatments for UTIs?Go to article: Pfizer and Takeda deals put a spotlight on value-based pricing Go to article: Lethal injection: can pharma kill the death penalty?Go to article: Mimotopes Company Insight Go to article: MimotopesGo to article: In DataGo to article: Middle-income countries’ healthcare sectors to keep rising through to 2024Go to article: Data analytics hiring levels in clinical trial operations rose in OctoberGo to article: Industrial automation innovation in pharma rebounded in the last quarterGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: YearbookGo to article: SHL MedicalGo to article: Dr. Paul Lohmann Company Insight Go to article: Dr. Paul LohmannGo to article: Novo NordiskGo to article: NiproGo to article: EventsGo to article: Next issue